0001193125-22-188291.txt : 20220706 0001193125-22-188291.hdr.sgml : 20220706 20220706084333 ACCESSION NUMBER: 0001193125-22-188291 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20220630 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220706 DATE AS OF CHANGE: 20220706 FILER: COMPANY DATA: COMPANY CONFORMED NAME: T2 Biosystems, Inc. CENTRAL INDEX KEY: 0001492674 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 204827488 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36571 FILM NUMBER: 221067466 BUSINESS ADDRESS: STREET 1: 101 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-457-1200 MAIL ADDRESS: STREET 1: 101 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 8-K 1 d370202d8k.htm 8-K 8-K
false 0001492674 --12-31 0001492674 2022-06-30 2022-06-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 30, 2022

 

 

T2 BIOSYSTEMS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36571   20-4827488

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

101 Hartwell Avenue, Lexington, Massachusetts 02421

(Address of principal executive offices, including Zip Code)

(781) 761-4646

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.001 per share   TTOO  

The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 3.03

Material Modification to Rights of Security Holders.

On June 30, 2022, the Board of Directors of T2 Biosystems, Inc. (the “Company”) approved and adopted an amendment to Article II, Section 2.8 of the Company’s Amended and Restated Bylaws to lower the quorum required for the transaction of business at all meetings of stockholders from the holders of a majority in voting power of the capital stock issued and outstanding and entitled to vote to the holders of at least one-third in voting power of the common stock issued and outstanding and entitled to vote (the “By-laws Amendment”).

The foregoing description of the By-laws Amendment does not purport to be complete and is qualified in its entirety by reference to the text of the By-laws Amendment, marked to show the changes, which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

The description of the By-laws Amendment in Item 3.03 is incorporated herein by reference.

 

Item 8.01

Other Events.

On July 6, 2022, the Company reported the following preliminary unaudited second quarter 2022 financial results:

 

  •  

Preliminary unaudited second quarter 2022 total revenue is expected to be $5.8 to $6.1 million, including product revenue of $2.5 to $2.7 million and research revenue of $3.3 to $3.4 million.

 

  •  

Executed contracts for 12 T2Dx® Instruments during the second quarter of 2022, consisting of 6 in the U.S. and 6 outside the U.S.

 

  •  

Implemented expense reductions on June 1, 2022, reducing the workforce by eliminating 34 existing and 20 planned positions, and decreasing operating expenses by approximately 20%.

 

  •  

Raised $4.6 million of net proceeds from the sale of 25.9 million shares through the ATM facility during the second quarter of 2022.

 

  •  

Cash and cash equivalent as of June 30, 2022, are expected to be approximately $14.3 million.

 

  •  

Amended Company bylaws to lower the quorum requirement at stockholder meetings from a majority to one-third of the common shares outstanding.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our revenue results and cash balance, financial outlook, cost improvement measures, timing of completion of clinical trials, anticipated strategic priorities, status of product development pipeline, product demand, commitments or opportunities, and growth expectations or targets,, as well as statements that include the words “expect,” “intend,” “plan”, “believe”, “project”, “forecast”, “estimate,” “may,” “should,” “anticipate,” and similar statements of a future or forward looking nature. These forward-looking statements are based on management’s current expectations. The preliminary, estimated financial results for the first quarter contained in this Current Report on Form 8-K contain forward-looking statements and are subject to the completion of management’s and the audit committee’s final reviews and our other financial closing procedures and are therefore subject to change. You should not place undue reliance on such preliminary information and estimates because they may prove to be materially inaccurate. The preliminary information and estimates have not been compiled or examined by our independent auditors and they are subject to revision as we prepare our financial statements as of and for the quarter ending June 30, 2022, including all disclosures required by U.S. generally accepted accounting principles, and as our auditors conduct their review of these financial statements. While we believe that such preliminary information and estimates are based on reasonable assumptions, actual results may vary, and such variations may be material.

These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission, or SEC, on March 23, 2022, and other filings the company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report on Form 8-K. Any such forward-looking statements represent management’s estimates as of the date of this Current Report on Form 8-K. While the company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this Current Report on Form 8-K.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

 

Exhibit

    No.    

   

Description

 3.1    Amendment to Amended and Restated By-laws of T2 Biosystems, Inc., effective June 30, 2022
99.1    Press Release issued July 6, 2022 announcing preliminary estimated financial results for the quarter ended June 30, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 6, 2022     T2 BIOSYSTEMS, INC.
    By:  

/s/ John Sprague

      John Sprague
      Chief Financial Officer
 EX-3.1 2 d370202dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

AMENDMENT TO ARTICLE II, SECTION 2.8 OF

AMENDED AND RESTATED BYLAWS

OF

T2 BIOSYSTEMS, INC.

(a Delaware corporation)

2.8 QUORUM.

Unless otherwise provided by law, the certificate of incorporation or these bylaws, the holders of a majority at least one-third in voting power of the capital stock common stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. A quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a quorum. If, however, a quorum is not present or represented at any meeting of the stockholders, then either (a) the chairperson of the meeting or (b) a majority in voting power of the stockholders entitled to vote thereon, present in person, or by remote communication, if applicable, or represented by proxy, shall have power to adjourn the meeting from time to time in the manner provided in Section 2.9 of these bylaws until a quorum is present or represented. At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed.

EX-99.1 3 d370202dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

T2 Biosystems Announces Preliminary Second Quarter 2022 Financial Results

Implemented expense reductions including headcount during the second quarter

LEXINGTON, Mass., July 6, 2020 (GLOBE NEWSWIRE)—T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial results for the quarter ended June 30, 2022.

Recent Highlights

 

  •  

Preliminary unaudited second quarter 2022 total revenue is expected to be $5.8 to $6.1 million, including product revenue of $2.5 to $2.7 million and research revenue of $3.3 to $3.4 million.

 

  •  

Executed contracts for 12 T2Dx® Instruments during the second quarter of 2022, consisting of 6 in the U.S. and 6 outside the U.S.

 

  •  

Implemented expense reductions on June 1, 2022, reducing the workforce by eliminating 34 existing and 20 planned positions, and decreasing operating expenses by approximately 20%.

 

  •  

Raised $4.6 million of net proceeds from the sale of 25.9 million shares through the ATM facility during the second quarter of 2022.

 

  •  

Cash and cash equivalent as of June 30, 2022 are expected to be approximately $14.3 million.

 

  •  

Amended Company bylaws to lower the quorum requirement at stockholder meetings from a majority to one-third in voting power of the common stock outstanding.

“We continued to make progress across our three corporate priorities during the second quarter of 2022, which included the execution of 12 T2Dx instrument contracts, an approximate 13% increase in sales of our sepsis test panels compared to the first quarter, the implementation of a significant cost-of-goods reduction initiative for our sepsis test panels, continued progress on the U.S. clinical trials for the T2Resistance Panel and the T2Biothreat Panel, and the continued development of our next-generation sepsis products,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “We also took proactive steps during the second quarter to reduce our operating expenses.”

The Company’s second quarter 2022 financial results are preliminary, subject to completion of internal procedures and review by our auditors. Complete second quarter 2022 financial results will be announced in early August.

2022 Financial Outlook

The Company continues to expect full year 2022 total revenue of $28.0 to $31.0 million, including product revenue of $16.0 to $17.0 million and research contribution revenue of $12.0 to $14.0 million. The Company continues to expect to close 60 to 70 T2Dx Instrument contracts in 2022 and COVID-19 revenue to decrease from $9.5 to $3.5 million.

About T2 Biosystems

T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Bacteria® Panel, T2Candida® Panel, T2Resistance® Panel, and T2SARS-CoV-2™ Panel and are powered by the Company’s proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, T2Lyme™ Panel, T2Biothreat Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers.

LOGO

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our revenue results and cash balance, financial outlook, cost improvement measures, timing of completion of clinical trials, anticipated strategic priorities, status of product development pipeline, product demand, commitments or opportunities, and growth expectations or targets, , as well as statements that include the words “expect,” “intend,” “plan”, “believe”, “project”, “forecast”, “estimate,” “may,” “should,” “anticipate,” and similar statements of a future or forward looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission, or SEC, on March 23, 2022, and other filings the company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

Investor Contact:

Philip Trip Taylor, Gilmartin Group

ir@T2Biosystems.com

415-937-5406

EX-101.SCH 4 ttoo-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 ttoo-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 ttoo-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g370202g87j00.jpg GRAPHIC begin 644 g370202g87j00.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Jun. 30, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001492674
Current Fiscal Year End Date --12-31
Document Type 8-K
Document Period End Date Jun. 30, 2022
Entity Registrant Name T2 BIOSYSTEMS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-36571
Entity Tax Identification Number 20-4827488
Entity Address, Address Line One 101 Hartwell Avenue
Entity Address, City or Town Lexington
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02421
City Area Code (781)
Local Phone Number 761-4646
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.001 per share
Trading Symbol TTOO
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 d370202d8k_htm.xml IDEA: XBRL DOCUMENT 0001492674 2022-06-30 2022-06-30 false 0001492674 --12-31 8-K 2022-06-30 T2 BIOSYSTEMS, INC. DE 001-36571 20-4827488 101 Hartwell Avenue Lexington MA 02421 (781) 761-4646 false false false false Common stock, par value $0.001 per share TTOO NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d370202d8k.htm d370202dex31.htm d370202dex991.htm ttoo-20220630.xsd ttoo-20220630_lab.xml ttoo-20220630_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d370202d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d370202d8k.htm" ] }, "labelLink": { "local": [ "ttoo-20220630_lab.xml" ] }, "presentationLink": { "local": [ "ttoo-20220630_pre.xml" ] }, "schema": { "local": [ "ttoo-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ttoo", "nsuri": "http://www.t2biosystems.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d370202d8k.htm", "contextRef": "duration_2022-06-30_to_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d370202d8k.htm", "contextRef": "duration_2022-06-30_to_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.t2biosystems.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-188291-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-188291-xbrl.zip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end